Skip to main content

02-23-2022 | Mental health | News

Depression screeners underestimate suicide risk in young people with type 1 diabetes

Author: Laura Cowen


medwireNews: The Patient Health Questionnaire (PHQ)-9, which screens for depressive symptoms, underestimates suicide risk in adolescents and young adults (AYA) with type 1 diabetes when compared with a validated suicide-specific measure, research shows.

Ashley Moss (University of Washington, Seattle, USA) and colleagues say their findings “suggest sole reliance on suicide-risk items on depression screeners may not be enough to reliably identify patients at risk for suicide.”

They evaluated the ability of suicide-risk items embedded within the self-reported PHQ-9 to identify the presence of suicide risk in 133 AYA with type 1 diabetes (mean age 19.6 years, 58% young women) seen in a multidisciplinary AYA Diabetes Program clinic.

“Reliable identification of [AYA] with type 1 diabetes at risk for suicide is critical given requisite access to insulin, which can be lethal when used for self-harm,” the researchers remark.

They report in Diabetes Care that, according to the PHQ-9, 13 (9.8%) participants were at risk for suicide.

However, when the cohort was assessed using the pediatric psychologist–administered Columbia-Suicide Severity Risk Survey (C-SSRS), which serves as a reference standard, 15 (11.3%) reported suicide risk.

Of the 15 participants identified as being at risk for suicide by C-SSRS, eight also screened positive on the PHQ-9. In addition, the PHQ-9 correctly identified the absence of suicide risk in 113 of 118 participants found not to be at risk by C-SSRS.

This resulted in a sensitivity of 53.3% for the PHQ-9 suicide risk item to identify people at risk, along with a specificity of 95.7%, a positive predictive value of 61.5%, and a negative predictive value of 94.2%.

The false-negative rate was 46.7% and the false-positive rate was 4.2%.

Moss et al suggest that “the PHQ-9 suicide-risk item may perform poorly because it does not directly ask about thoughts of killing oneself nor does it delineate between passive thoughts about death and self-harm ideation.”

The authors conclude: “Given mounting evidence of suicide risk in this population, clinical guidelines should explicitly recommend use of validated, suicide-specific screeners in addition to routine depression screening as a part of comprehensive medical care for this vulnerable population.”

They add: “The findings of this study also reinforce the critical role of embedded behavioral health resources as part of a multidisciplinary team to address the needs of this unique population.”

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group

Diabetes Care 2022; doi:10.2337/dc21-1553


Novel clinical evidence in continuous glucose monitoring

Novel clinical evidence in continuous glucose monitoring

How real-world studies complement randomized controlled trials

Jean-Pierre Riveline uses data from real-life continuous glucose monitoring studies to illustrate how these can uncover critical information about clinical outcomes that are hard to assess in randomized controlled trials.

This video has been developed through unrestricted educational funding from Abbott Diabetes Care.

Watch the video